Provided are a sesquiterpene derivative represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition including the same and a PD-1 antibody as active components, as well as a preparation method and use thereof; in formula (I), R.sub.1 and R.sub.2 independently are selected from the group consisting of alkyl and hydroxyalkyl, with the proviso that R.sub.1 and R.sub.2 are not simultaneously methyl.

##STR00001##

Disclosed is a method of catalytic oxidation of lignite using oxygen as an oxidant at atmospheric pressure, belonging to a method of mild oxidation of lignite. The method is used to mildly oxidize the lignite using the oxygen as the oxidant under the action of a nitroxide radical catalyst and a metal salt or metal oxide cocatalyst; the process comprises the following steps: pulverizing the lignite to 200 meshes or less, drying a pulverized coal sample at a temperature of 80 C. in vacuum for 10 h, weighing 0.5 g of the treated coal sample, sequentially adding 10 ml of acetic acid, 0.5 mmol of a catalyst and 0.15 to 0.25 mmol of a cocatalyst into a round-bottom flask, connecting a tee joint to an upper orifice of a condenser pipe, replacing oxygen in vacuum for three times so that the round-bottom flask is filled with the oxygen, keeping oxygen pressure at 0.1 MPa, reacting at a temperature of 80 C. to 120 C. for 4 to 12 h; filtering after the reaction is finished; decompressing a filtrate to remove the acetic acid, adding a small amount of ethyl acetate to dissolve, then using an excess CH.sub.2N.sub.2/ether solution to esterify for 10 h at room temperature, using 0.45 m filter paper to filter, and analyzing an esterified product through a gas chromatography-mass spectrometer. The method has the advantages of using the oxygen as the oxidant, having low price, having no toxicity, and achieving environmental protection and mild conditions.

Disclosed is a method of catalytic oxidation of lignite using oxygen as an oxidant at atmospheric pressure, belonging to a method of mild oxidation of lignite. The method is used to mildly oxidize the lignite using the oxygen as the oxidant under the action of a nitroxide radical catalyst and a metal salt or metal oxide cocatalyst; the process comprises the following steps: pulverizing the lignite to 200 meshes or less, drying a pulverized coal sample at a temperature of 80 C. in vacuum for 10 h, weighing 0.5 g of the treated coal sample, sequentially adding 10 ml of acetic acid, 0.5 mmol of a catalyst and 0.15 to 0.25 mmol of a cocatalyst into a round-bottom flask, connecting a tee joint to an upper orifice of a condenser pipe, replacing oxygen in vacuum for three times so that the round-bottom flask is filled with the oxygen, keeping oxygen pressure at 0.1 MPa, reacting at a temperature of 80 C. to 120 C. for 4 to 12 h; filtering after the reaction is finished; decompressing a filtrate to remove the acetic acid, adding a small amount of ethyl acetate to dissolve, then using an excess CH.sub.2N.sub.2/ether solution to esterify for 10 h at room temperature, using 0.45 m filter paper to filter, and analyzing an esterified product through a gas chromatography-mass spectrometer. The method has the advantages of using the oxygen as the oxidant, having low price, having no toxicity, and achieving environmental protection and mild conditions.

Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.

This application relates to various salts and solid state forms of Compound (I). This application also relates to pharmaceutical compositions and therapeutic uses of these materials and compositions.

The invention provides a pharmaceutically acceptable salt of 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile which is selected from maleate, tosylate, besylate and malonate salts.

Also provided are particular crystalline forms of the salts, methods for the preparation of the salts, pharmaceutical compositions containing the salts and their therapeutic uses.

The invention provides a pharmaceutically acceptable salt of 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile which is selected from maleate, tosylate, besylate and malonate salts.

Also provided are particular crystalline forms of the salts, methods for the preparation of the salts, pharmaceutical compositions containing the salts and their therapeutic uses.

Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.

The present invention provides a malonate salt of a compound of formula (I): ##STR00001##
which is a crystalline salt. Also provided are pharmaceutical compositions that include the provided malonate salt and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.

The present invention provides a malonate salt of a compound of formula (I): ##STR00001##
which is a crystalline salt. Also provided are pharmaceutical compositions that include the provided malonate salt and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.